Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age

NCT01457547 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01457547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01457547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2003
Completion date
May 31, 2005
Enrollment
494 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, haemophilus influenzae type b, hepatitis b, poliomyelitis, tetanus